AI Article Synopsis
- Interleukin-15 (IL-15) was discovered in 1994 as a growth factor for T-cells and imitates some functions of IL-2.
- It activates immune responses by interacting with the IL-15Rα on antigen-presenting cells, which then stimulates NK cells and CD8+ T cells through a specific receptor complex.
- IL-15 plays a significant role in enhancing the survival and proliferation of these immune cells, making it a promising target for developing new cancer immunotherapies.
Article Abstract
Interleukin-15 (IL-15) was identified in 1994 as a T-cell growth factor with the capability to mimic the functions of IL-2. IL-15 engages with the IL-15Rα subunit expressed on the surface of antigen-presenting cells (APCs) and, through a trans-presentation mechanism, activates the IL-2/IL-15Rβγ complex receptor on the surface of natural killer (NK) cells and CD8+ T cells. This interaction initiates a cascade of downstream signaling pathways, playing a pivotal role in the activation, proliferation, and anti-apoptotic processes in NK cells, CD8+ T cells, and B cells. It provides a substantial theoretical foundation and potential therapeutic targets for tumor immunotherapy. Whether through active or passive immunotherapeutic strategies, IL-15 has emerged as a critical molecule for stimulating anti-tumor cell proliferation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0118715206321574240821112747 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Galectin-3 secreted by triple-negative breast cancer cells regulates T cell function.
Neoplasia
December 2024
Felsenstein Medical Research Center, Beilinson Campus, Petah Tikva, Israel; Tel Aviv University, Faculty of Medicine and Health Sciences, Tel Aviv, Israel; Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel; Davidoff Cancer Center, Beilinson Campus, Petah Tikva, Israel. Electronic address:
Triple-negative breast cancer (TNBC) is an aggressive subtype that accounts for 10-15 % of breast cancer. Current treatment of high-risk early-stage TNBC includes neoadjuvant chemo-immune therapy. However, the substantial variation in immune response prompts an urgent need for new immune-targeting agents.
View Article and Find Full Text PDF[Immunomodulatory therapy in the postoperative period in chronic purulent otitis media].
Vestn Otorinolaringol
December 2024
Dagestan State Medical University, Makhachkala, Russia.
Unlabelled: This paper presents the results of the evaluation of cellular and humoral immunity in chronic purulent otitis media (CPOM), as well as cytokine status, and studies the effect of azoximers bromide on the immunity system in CPOM.
Objective: To study the clinical and immunologic effectiveness of azoximer bromide in the postoperative period during tympanoplasty in CPOM patients.
Material And Methods: Forty-nine patients with mesotympanitis and epitympanitis were examined.
Background: Osteosarcoma (OS) is the most common primary bone malignancy in the world. Increasing studies indicate that long non-coding RNAs (lncRNAs) are involved in ferroptosis and OS progression. Therefore, this study aims to identify ferroptosis- related lncRNAs (frlncRNAs), explore potential competing endogenous RNA (ceRNA) networks, and establish a new model for predicting OS prognosis.
View Article and Find Full Text PDFActivin A promoted the anti-tumor effect of ActRIIA CD8 T cells in mouse hepatoma.
Cancer Med
January 2025
Department of Clinical Laboratory, Affiliated Hospital of Shandong Second Medical University, Weifang, China.
Background: Activin A, a noteworthy member of the TGF-β superfamily. Activin A can regulate the biological functions of various immune cells, such as macrophages, neutrophils, NK cells, etc. The purpose of this study is to investigate the regulatory effect and related mechanisms of activin A on CD8 T cells.
View Article and Find Full Text PDFAloe-emodin plus TIENAM ameliorate cecal ligation and puncture-induced sepsis in mice by attenuating inflammation and modulating microbiota.
Front Microbiol
December 2024
First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, Fujian, China.
Despite the high sepsis-associated mortality, effective and specific treatments remain limited. Using conventional antibiotics as TIENAM (imipenem and cilastatin sodium for injection, TIE) is challenging due to increasing bacterial resistance, diminishing their efficacy and leading to adverse effects. We previously found that aloe-emodin (AE) exerts therapeutic effects on sepsis by reducing systemic inflammation and regulating the gut microbiota.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!